临床医生对基于证据的心力衰竭和减少喷射率的处方提出挑战:定性评估
Katy E Trinkley1,2,3,4, Ashley Dafoe4, Daniel C Malone5
1Department of Family Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Journal of evaluation in clinical practice
|June 19, 2023
概括
临床医生在处方指南导向心力衰竭与减少喷射率 (HFrEF) 药物时面临着持续的和新的挑战,影响患者的护理. 了解这些障碍是改善治疗坚持和治疗结果的关键.
科学领域:
- 心脏病学 心脏病学
- 临床药房 临床药房
- 医疗保健管理的管理
背景情况:
- 对心力衰竭的低最佳处方与减少喷射率 (HFrEF) 是一个已知的问题.
- 最近的医疗保健进步可能改变了这些处方挑战.
- 目前临床医生对指导方针导向的HFrEF药物治疗的障碍仍然不清楚.
研究的目的:
- 识别和理解当前临床医生对处方指南导向的HFrEF药物的挑战.
主要方法:
- 使用了内容分析方法.
- 与初级保健和心脏病学临床医生进行了采访和成员检查焦点小组.
- 面试指南通过Cabana框架获取信息.
主要成果:
- 确定了四个临床医生所感知的挑战水平:临床医生,患者临床医生,临床医生临床医生,以及政策/系统/组织.
- 临床医生层面的障碍包括误解,关于成本的假设和临床惯性.
- 临床间的挑战涉及角色明确性和对新药安全性的不同信心,而系统层面的问题包括数据访问和激励指标.
结论:
- 目前对指导方针指导的HFrEF护理的挑战仍然存在,新的障碍正在出现.
- 对立的专家/一般主义观点以及对新药安全性的担忧是显著的.
- 基于价值的报销指标可能会造成意想不到的护理差距,需要进行战略干预.
相关概念视频
Heart Failure VII: Nursing Interventions
118
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
118
Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
469
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
469
Cardiomyopathy V: Interprofessional Care
18
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
18
Heart Failure Drugs: β-Blockers
382
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
382


